Germany's Institute for Quality and Efficiency in Health Care (IQWiG) developed a matrix to quantify a drug's level of additional benefit vs. a comparator. The table sets relative risk (RR) thresholds that determine the extent of additional benefit based on statistical measures of mortality, morbidity, adverse events and quality of life (QOL). Drugs are deemed to have a major, considerable or minor additional